Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X0OF
|
||||
| Former ID |
DNCL003026
|
||||
| Drug Name |
Pennvax-G
|
||||
| Synonyms |
Pennvax-G (TN)
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] | Phase 1 | [1] | ||
| Company |
Inovio Pharmaceuticals
|
||||
| Target and Pathway | |||||
| Target(s) | Human DNA | Target Info | [2] | ||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01260727) Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults. U.S. National Institutes ofHealth. | ||||
| REF 2 | Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.